Petros Pharmaceuticals (NasdaqCM:PTPI) - Share price, News & Analysis

PTPI fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

PTPI Stock Overview

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men’s health therapeutics.

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months

Does not have a meaningful market cap ($16M)

Petros Pharmaceuticals Competitors

Pulmatrix

NasdaqCM:PULM

US$15.9m

Clarus Therapeutics Holdings

NasdaqGM:CRXT

US$16.8m

NovaBay Pharmaceuticals

NYSEAM:NBY

US$15.0m

Aytu BioPharma

NasdaqCM:AYTU

US$17.6m

Price History & Performance

Summary of all time highs, changes and price drops for Petros Pharmaceuticals
Historical stock prices
Current Share Price	US$0.78
52 Week High	US$5.20
52 Week Low	US$0.65
Beta	0
1 Month Change	-5.32%
3 Month Change	-18.01%
1 Year Change	-74.21%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-80.48%

Recent News & Updates

Aug 15

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Petros Pharmaceuticals press release (NASDAQ:PTPI): Q2 GAAP EPS of -$0.10. Revenue of $6.6M (+0.9% Y/Y).

Jul 28

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Private investment group Henry Crown and Company (HCC) will acquire men's health firm Petros Pharmaceuticals (NASDAQ:PTPI) for $3.25 per share in an all-cash transaction for a total equity value of about $67.2M, the companies said on Thursday. The deal value of $3.25 per share represents a 306.25% premium to PTPI's last closing price of $0.80. PTPI shares zoomed on the announcement, more than tripling in value to $2.63. As per the deal, CVF LLC, an affiliate managing HCC's healthcare investments, will acquire all the outstanding shares of PTPI, which will become a privately-owned company at the close of the transaction. PTPI's board has unanimously approved the merger. HCC expects to finance the deal with existing cash on hand. The companies expect the merger to close by early 2023. The merger also includes the acquisition of PTPI's assets including erectile dysfunction (ED) drug Stendra, a treatment candidate for Peyronie's disease called H100 and a line of medical devices for the treatment of ED.

Shareholder Returns

	PTPI	US Pharmaceuticals	US Market
7D	-1.4%	1.0%	3.2%
1Y	-74.2%	1.3%	-10.2%

Return vs Industry: PTPI underperformed the US Pharmaceuticals industry which returned 1.3% over the past year.

Return vs Market: PTPI underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is PTPI's price volatile compared to industry and market?
PTPI volatility
PTPI Average Weekly Movement	12.2%
Pharmaceuticals Industry Average Movement	12.1%
Market Average Movement	7.7%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: PTPI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: PTPI's weekly volatility has decreased from 26% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	24	Fady Boctor	https://www.petrospharma.com

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men’s health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie’s disease.

Petros Pharmaceuticals Fundamentals Summary

How do Petros Pharmaceuticals's earnings and revenue compare to its market cap?
PTPI fundamental statistics
Market Cap	US$16.11m
Earnings (TTM)	-US$11.87m
Revenue (TTM)	US$7.93m

2.0x

P/S Ratio

-1.4x

P/E Ratio

Is PTPI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTPI income statement (TTM)
Revenue	US$7.93m
Cost of Revenue	US$1.68m
Gross Profit	US$6.25m
Other Expenses	US$18.11m
Earnings	-US$11.87m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.57
Gross Margin	78.76%
Net Profit Margin	-149.68%
Debt/Equity Ratio	29.3%

How did PTPI perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is PTPI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PTPI?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for PTPI. This is calculated by dividing PTPI's market cap by their current preferred multiple.
What is PTPI's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$16.11m

PTPI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.6x
Enterprise Value/EBITDA	-1.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PTPI's PS Ratio compare to its peers?

PTPI PS Ratio vs Peers

The above table shows the PS ratio for PTPI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	1.7x
PULM Pulmatrix	4x	43.6%	US$15.9m
CRXT Clarus Therapeutics Holdings	1.1x	41.9%	US$16.8m
NBY NovaBay Pharmaceuticals	1.5x	35.2%	US$15.0m
AYTU Aytu BioPharma	0.2x	9.3%	US$17.6m
PTPI Petros Pharmaceuticals	2x	n/a	US$16.1m

Price-To-Sales vs Peers: PTPI is expensive based on its Price-To-Sales Ratio (2x) compared to the peer average (1.7x).

Price to Earnings Ratio vs Industry

How does PTPI's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: PTPI is good value based on its Price-To-Sales Ratio (2x) compared to the US Pharmaceuticals industry average (3.7x)

Price to Sales Ratio vs Fair Ratio

What is PTPI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PTPI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PTPI's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of PTPI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PTPI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PTPI's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Petros Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

10.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Petros Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Take a look at our analysis of PTPI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Petros Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

46.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PTPI is currently unprofitable.

Growing Profit Margin: PTPI is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: PTPI is unprofitable, but has reduced losses over the past 5 years at a rate of 46.9% per year.

Accelerating Growth: Unable to compare PTPI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTPI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).

Return on Equity

High ROE: PTPI has a negative Return on Equity (-34.69%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Petros Pharmaceuticals's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PTPI's short term assets ($22.9M) exceed its short term liabilities ($7.4M).

Long Term Liabilities: PTPI's short term assets ($22.9M) exceed its long term liabilities ($9.5M).

Debt to Equity History and Analysis

Debt Level: PTPI has more cash than its total debt.

Reducing Debt: Insufficient data to determine if PTPI's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTPI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PTPI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 63.6% each year

Discover healthy companies

Dividend

What is Petros Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTPI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTPI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTPI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTPI's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PTPI has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure

CEO

Fady Boctor (44 yo)

2.58yrs

Tenure

US$1,177,821

Compensation

Mr. Fady Boctor, MBA, has been the President and Chief Commercial Officer of Petros Pharmaceuticals, Inc. since 2020 and serves as its Principal Executive Officer. Mr. Boctor has experience in the pharmace...

CEO Compensation Analysis

Compensation vs Market: Fady's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD759.99K).

Compensation vs Earnings: Fady's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: PTPI's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Experienced Board: PTPI's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 111.1%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/14 00:00
End of Day Share Price	2022/08/12 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31